Contact: Vicki Cohn, (914) 740-2156, firstname.lastname@example.org
Ronald Crystal, MD, Receives Pioneer Award for Developing First In Vivo Adenoviral Gene Delivery Vector
New Rochelle, NY, January 31, 2014—In recognition of his seminal work on adenoviral vectors, which accelerated the translation of gene therapy from the research laboratory to the clinic, Ronald G. Crystal, MD (Weill Cornell Medical College, Cornell University, New York City), has received a Pioneer Award from Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Human Gene Therapy is commemorating its 25th anniversary by bestowing this honor on the leading 12 Pioneers in the field of cell and gene therapy selected by a blue ribbon committee* and publishing a Pioneer Perspective by each of the award recipients. The article by Dr. Crystal is available free on the Human Gene Therapy website.
Currently it is standard practice to use a modified virus as a transport vehicle to deliver therapeutic genes to patients. But this concept was new, innovative, and technically challenging when Dr. Crystal began developing the molecular tools and methods in the late 1980s. In the Pioneer Perspective “Adenovirus: The First Effective In Vivo Gene Delivery Vector,” Dr. Crystal provides historical insights on the many years of research and testing needed to design, optimize, manufacture, and evaluate the performance of adenoviral vectors. He describes the first in vivo studies, the first human studies, and the many current applications of this useful gene delivery system.
"Ron led the way in the clinical translation of adenoviral vectors in the very early days of gene therapy," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.
*The blue ribbon panel of leaders in cell and gene therapy, led by Chair Mary Collins, PhD, MRC Centre for Medical Molecular Virology, University College London, selected the Pioneer Award recipients. The Award Selection Committee selected scientists that had devoted much of their careers to cell and gene therapy research and had made a seminal contribution to the field--defined as a basic science or clinical advance that greatly influenced progress in translational research.
About the Journal
Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of content for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.